Retina

The company also submitted a marketing authorization application with the European Medicines Agency.

Respecting the clinical importance of the pachychoroid spectrum is vital when analyzing OCT scans.

Neurotech's ocular implant NT-501 utilizes encapsulated cell therapy to slow the progression of macular telangiectasia type 2 (MacTel). The implant was given a PDUFA goal date of December 17, 2024.

Pathogenesis and detection of diabetic retinopathy.

The study evaluates the efficacy, safety, and tolerability of 2 dose levels of AGTC-501 for the treatment of X-linked retinitis pigmentosa.

Positive data from the GALE long-term extension study showed patients developed fewer new scotomatous points with 36 months of both continuous monthly and every-other-month treatment.

The French study found that a complete capsular removal seemed to be the safer option for pediatric patients with Marfan syndrome in terms of risk of retinal detachment.

The biotechnology company is developing the first protein-based artificial retina for patients with retinitis pigmentosa and age-related macular degeneration.

DF-003 is a first-in-class, oral, potent, highly selective alpha-kinase 1 (ALPK1), an inhibitor believed to be responsible for causing ROSAH syndrome.

The trial evaluates OCU410ST, a modifier gene therapy candidate utilizing an AAV delivery platform for the retinal delivery of the RORA gene. The gene therapy is being designed as a one-time treatment for life.

The AI-powered eye diagnostic innovator and medical devices and software solutions company have announced a collaboration to promote an AI diagnostic tool that assesses risk to brain health via retinal imaging.

The Diffusion Optics Technology, or DOT 0.2, works by utilizing thousands of light scattering elements to mimic natural contrast on the retina, which can slow myopia progression in child, according to the company.

The technology works by concentrating a specific band of light, typically 650 nm, into a laser beam to irradiate the retina.

The diagnostic screening technology is able to diagnose diabetic retinopathy by using 1 image taken of each eye with over 99% imageability.

The non-randomized, open label, safety and efficacy study will inject a sustained release implant in 5 participants.

Early detection of incipient geographic atrophy is critical to identify patients at greatest risk of progression and who may benefit most from newly approved complement inhibition therapies.

The AI-powered model works to detect early signs of glaucoma and makes iHealthScreen the first company to receive 2 US patents for AMD and glaucoma screening devices.

The goal of the grant funding from the Choroideremia Research Foundation is to support validation of functional vision assessments for patients with profound blindness.

The company stated that 46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the Axpaxli arm, compared to 0% in the control arm.

The Phase 1/2 study includes a dose-escalation phase of the study featuring 3 cohorts each one receiving either a low, medium, or high dose of OCU410.

The Phase 3 study will have a sample size of 150 participants—one arm of 75 participants with the RHO gene mutation and the other arm with 75 participants that are gene agnostic.

The effort led to the creation of an artificial vitreous body for treating retinal detachment. This solution is based on a natural carbohydrate derived from algae.

MCO-010 demonstrated a statistically significant improvement of best-corrected visual acuity (BCVA) at week 52.

Cleveland, Ohio’s Great Lakes Science Center Community Engagement Coordinator JonDarr Bradshaw details what those in the path of totality should expect, as well as the science center’s initiatives to keep eyes healthy during the event.

Prevent Blindness and the American Optometric Association have released resources and educational information to help the public and eye care providers prepare for the astronomical event on April 8.

The authors suggested genetic mutation may relax the body’s defenses and allow harmful bacteria to reach the eye.

The study focuses on similarities and differences in 11-cis-retinal and mutations in carotenoid cleavage enzymes.

Findings from Mass Eye and Ear’s collaborative study provides new insights regarding gene expression and post-transcriptional gene regulation.

The program, announced prior to ROP Awareness Week, has established an ROP-specific website with free resources for parents and eye care professionals.

According to the company, AGTC-501 was generally safe and well-tolerated and showed improvements in visual function at the 12-month analysis. The Phase 2/3 VISTA trial for AGTC-501 in XLRP expected to begin in in the first half of 2024.